Importantly, targeting MSLN high expressed liver metastasis breast cancer with a Paclitaxel/Carboplatin combination displayed a significant anti-metastatic effect, suggesting that targeting MSLN-EGFR-ERK signaling could be an effective strategy for treating TNBC liver metastases. This evidence concerns the gene MSLN and breast carcinoma.